MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
MicroRNAs (miRNAs) are involved in human cancers including myeloma. MiR-19a is one of the oncogenic miR-17-92 clusters, which is identified as a key oncogenic component in many cancers. Nevertheless, the function of miR-19a in myeloma has not been totally elucidated. The purpose of this study is to investigate the biological functions of miR-19a in MM. In vitro, we detected that the miR-19a-3p is overexpressed in myeloma cells. The proliferation and invision of myeloma cells are analyzed by MTT and BD matrigel assays, respectively. Western blot was performed to evaluate the expression of apoptotic/drug resistance-related main control proteins BCL-2 and MDR1 in myeloma cells after transfected with miR-19a-3p. Finally, we found miR-19a acts as an oncogene in MM by promoting cell proliferation/invision and inhibiting apoptosis. Additionally, We further showed that the mRNA and protein of BCL-2 and MDR were upregulated significantly after elevated expression of miR-19a, the process of which was regulated by PTEN/AKT/pAKT-signaling pathway. Our results suggest that miR-19a acted as an oncogenic miRNA by targeting PTEN in myeloma. This novel miR-19a/PTEN/AKT axis sheds new light on the mechanisms underlying apoptosis and invision and may provide potentially therapeutic targets for the treatment of myeloma.
a Department of Hematology, Key Laboratory of Cancer Prevention and Therapy , Tianjin Medical University, Cancer Hospital of Tianjin , Tianjin , China.
Xiaoying
X
Zhang
a Department of Hematology, Key Laboratory of Cancer Prevention and Therapy , Tianjin Medical University, Cancer Hospital of Tianjin , Tianjin , China.
Yafang
Y
Chen
a Department of Hematology, Key Laboratory of Cancer Prevention and Therapy , Tianjin Medical University, Cancer Hospital of Tianjin , Tianjin , China.
Pan
P
Zhao
a Department of Hematology, Key Laboratory of Cancer Prevention and Therapy , Tianjin Medical University, Cancer Hospital of Tianjin , Tianjin , China.
Li
L
Zang
b Department of Neurology , The Fourth Central Hospital , Tianjin , China.
Zhiqing
Z
Zhang
a Department of Hematology, Key Laboratory of Cancer Prevention and Therapy , Tianjin Medical University, Cancer Hospital of Tianjin , Tianjin , China.
Xiaofang
X
Wang
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D002470:Cell Survival / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism*; D009857:Oncogenes; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction
D000970:Antineoplastic Agents; C549214:MIRN19A microRNA, human; D035683:MicroRNAs; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
AKT; PTEN; apoptosis; invision; miRNA-19a; pAKT